278 related articles for article (PubMed ID: 93365)
1. Circulating immune complexes in lupus erythematosus, scleroderma and dermatomyositis.
Sølling J; Sølling K; Jacobsen KU
Acta Derm Venereol; 1979; 59(5):421-6. PubMed ID: 93365
[TBL] [Abstract][Full Text] [Related]
2. Determination of circulating immune complexes, C3 and C4 complement components and anti-DNA antibody in different classes of lupus nephritis.
Klein MH; Thorner PS; Yoon SJ; Poucell S; Baumal R
Int J Pediatr Nephrol; 1984 Jun; 5(2):75-82. PubMed ID: 6333404
[TBL] [Abstract][Full Text] [Related]
3. The specific detection of IgG, IgA and the complement components C3 and C4 in circulating immune complexes.
Valentijn RM; van Es LA; Daha MR
J Clin Lab Immunol; 1984 Jun; 14(2):81-6. PubMed ID: 6748050
[TBL] [Abstract][Full Text] [Related]
4. Circulating immune complexes in systemic lupus erythematosus: a reappraisal of the solid phase C1q radioimmunoassay.
Woodroffe AJ; Nozza JM; Muller KD; McIntosh SL; Hale GM; Clarkson AR
J Clin Lab Immunol; 1988 May; 26(1):5-7. PubMed ID: 3263507
[TBL] [Abstract][Full Text] [Related]
5. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
Sakurai T; Fujita T; Kono I; Kabashima T; Yamane K; Tamura N; Kashiwagi H
Clin Exp Immunol; 1982 Apr; 48(1):37-42. PubMed ID: 6979449
[TBL] [Abstract][Full Text] [Related]
6. Suppression of Fc Receptor and C4.C3 receptors of the granulocytes from patients with systemic lupus erythematosus.
Shingu M; Todoroki T; Sakai K; Nobunaga M
J Rheumatol; 1981; 8(6):910-6. PubMed ID: 7328566
[TBL] [Abstract][Full Text] [Related]
7. Correlation of C3d fixing circulating immune complexes with disease activity and clinical parameters in patients with systemic lupus erythematosus.
Sekita K; Doi T; Muso E; Yoshida H; Kanatsu K; Hamashima Y
Clin Exp Immunol; 1984 Mar; 55(3):487-94. PubMed ID: 6608422
[TBL] [Abstract][Full Text] [Related]
8. Immune complexes in systemic sclerosis; detection by C1q binding, K-cell inhibition and Raji cell radioimmunoassays.
Hughes P; Cunningham J; Day M; Fitzgerald JC; French MA; Wright JK; Rowell NR
J Clin Lab Immunol; 1983 Mar; 10(3):133-8. PubMed ID: 6601718
[TBL] [Abstract][Full Text] [Related]
9. [Circulating immune complexes in SLE by polyethylenglycol precipitation-complement consumption test].
Yotsumoto H; Shimokawa Y; Nomoto S; Tashiro M
Nihon Hifuka Gakkai Zasshi; 1983 Feb; 93(3):287-90. PubMed ID: 6348349
[No Abstract] [Full Text] [Related]
10. Relationship between anti-DNA antibodies complement consumption and circulating immune complexes in systemic lupus erythematosus.
Davis P; Cumming RH; Verrier-Jones J
Clin Exp Immunol; 1977 May; 28(2):226-32. PubMed ID: 301447
[TBL] [Abstract][Full Text] [Related]
11. Circulating immune complexes and the complements system in lupus nephropathy.
Serban MG
Rom J Intern Med; 1992; 30(2):119-25. PubMed ID: 1496264
[TBL] [Abstract][Full Text] [Related]
12. Specific detection of circulating DNA:anti-DNA immune complexes in human systemic lupus erythematosus sera using murine monoclonal anti-DNA antibody.
Tron F; Letarte J; Roque-Antunes Barreira MC; Lesavre P
Clin Exp Immunol; 1982 Aug; 49(2):481-7. PubMed ID: 6982138
[TBL] [Abstract][Full Text] [Related]
13. Erythrocyte complement receptor type 1 in patients with systemic lupus erythematosus.
Yen JH; Liu HW; Lin SF; Chen JR; Chen TP
J Rheumatol; 1989 Oct; 16(10):1320-5. PubMed ID: 2810256
[TBL] [Abstract][Full Text] [Related]
14. [Detection of circulating antibodies in the blood and immune complex precipitates of patients with autoimmune diseases (preliminary report)].
Kiss M; Husz S; Dobozy A
Orv Hetil; 1992 May; 133(18):1103-4, 1109-10. PubMed ID: 1579350
[TBL] [Abstract][Full Text] [Related]
15. A longitudinal study of circulating immune complexes, dna antibodies and complement in patients with systemic lupus erythematosus: an analysis of their relationship to disease activity.
Harkiss GD; Hazleman BL; Brown DL
J Clin Lab Immunol; 1979 Nov; 2(4):275-83. PubMed ID: 537024
[TBL] [Abstract][Full Text] [Related]
16. Pleural fluid complement, complement conversion, and immune complexes in immunologic and nonimmunologic diseases.
Hunder GG; McDuffie FC; Huston KA; Elveback LR; Hepper NG
J Lab Clin Med; 1977 Dec; 90(6):971-80. PubMed ID: 597373
[TBL] [Abstract][Full Text] [Related]
17. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
[TBL] [Abstract][Full Text] [Related]
18. Circulating immune complex levels measured by new ELISA kits utilizing monoclonal anti-C1q and anti-C3d antibodies correlate with clinical activities of SLE but not with those of RA.
Yoshinoya S; Mizoguchi Y; Aotsuka S; Yokohari R; Nishioka K; Miyamoto T
J Clin Lab Immunol; 1992; 38(4):161-73. PubMed ID: 11270517
[TBL] [Abstract][Full Text] [Related]
19. Reduced complement receptor 1 (CR1, CD35) transcription in systemic lupus erythematosus.
Arora V; Verma J; Dutta R; Marwah V; Kumar A; Das N
Mol Immunol; 2004 Jun; 41(4):449-56. PubMed ID: 15163541
[TBL] [Abstract][Full Text] [Related]
20. Solubilization of immune complexes and inhibition of immune precipitation in SLE sera.
Balestrieri G; Pagani D; Tincani A
J Clin Lab Immunol; 1983 Nov; 12(3):147-50. PubMed ID: 6663608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]